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with cardiovascular disease, including heart 
failure (HF).
Organization of care for patients with coronavirus 
disease 2019 in Poland To prevent the spread of 
the epidemic, on March 14, 2020, Poland intro‑
duced the state of epidemic emergency in con‑
nection with SARS ‑CoV‑2 infection, followed by 
the state of the epidemic since March 20, 2020. 
This made it possible to take a set of preventive 
antiepidemic actions, as specified in a legisla‑
tive act, to minimize the effects of the epidemic.
From March 16, 2020, 19 hospitals have been 
transformed into infectious disease hospitals 
that admit only patients with SARS ‑CoV‑2 in‑
fection. At least 10% of the beds in such a hos‑
pital should be dedicated to respiratory thera‑
py. These are multispecialty hospitals so that 
they can treat comorbidities in addition to 
Introduction Epidemiology of severe acute re-
spiratory syndrome coronavirus 2 infection At the 
end of 2019, a  new virus, known as severe 
acute respiratory syndrome coronavirus 2 
(SARS ‑CoV‑2), caused an epidemic of acute re‑
spiratory disease in Wuhan, China.1 The World 
Health Organization (WHO) called this condi‑
tion coronavirus disease 2019 (COVID‑19). By 
the time this position statement was submitted, 
COVID‑19 has become a pandemic and is affect‑
ing more and more people in the world and in Po‑
land (current data are available at: https://www.
worldometers.info/coronavirus/#countries). 
Both the WHO and Centers for Disease Con‑
trol and Prevention have issued preliminary 
guidelines for infection control, screening, and 
diagnosis in the general population. However, 
the existing guidelines are incomplete regard‑


















Severe acute respiratory syndrome coronavirus 2 (SARS ‑CoV‑2), a new coronavirus that induces acute 
respiratory failure among other conditions, is the cause of the rapidly spreading coronavirus disease 
2019 (COVID‑19), affecting thousands of people around the world. The present expert opinion is a synthetic 
summary of the current knowledge on the various aspects of heart failure in patients with COVID‑19. 
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damage to cardiac muscle cells. A study conducted 
during the SARS epidemic in 2002 revealed that 
35% of patients with acute respiratory distress 
syndrome (ARDS) had the SARS ‑CoV‑positive ge‑
nome in the heart.7 Thus, the virus can cause di‑
rect damage to the heart or affect the cardiovas‑
cular system indirectly through systemic proin‑
flammatory stimulation (cytokine storm: high lev‑
els of interleukins [IL‑1β, IL‑6] and interferon ‑γ 
as well as immune response dysregulation) or as 
a consequence of ARDS8 (FIGURE 1). Chinese authors 
reported elevated troponin levels in 12% to 28% 
of patients with COVID‑19.9-11 The increase in tro‑
ponin levels during hospitalization was signifi‑
cantly correlated with higher levels of N ‑termi‑
nal fragment of the prohormone brain natriuret‑
ic peptide (NT ‑proBNP) and C ‑reactive protein.9 
In addition, in patients who died during hospital‑
ization, troponin and NT ‑proBNP levels increased 
significantly compared with admission values, 
while no significant dynamic changes were not‑
ed among those who survived to discharge.9 Ele‑
vated troponin T and NT ‑proBNP levels, and es‑
pecially their dynamic changes during hospital‑
ization, proved to be a strong predictor of death 
in patients with COVID‑19.9
High ‑risk patients Patients at high risk for se-
vere course of severe acute respiratory syndrome 
coronavirus 2 infection Patients aged 60 years 
or older are at risk for a more severe course of 
SARS ‑CoV‑2 infection than children, who are 
at lower risk of infection and, if infected, may 
be mildly symptomatic or asymptomatic.12 Com‑
pared with patients aged 30 to 59 years, those 
younger than 30 years and older than 59 years 
were 0.6 (0.3–1.1) and 5.1 (4.2–6.1) times, re‑
spectively, more likely to die after developing 
symptoms.13 The risk of symptomatic infection 
increased with age (approximately 4% per year 
in adults aged 30 to 60 years).13
The severe course of SARS ‑CoV‑2 infection is 
becoming a serious issue in the context of HF 
and its increasing incidence due to population 
aging, among other factors. Population aging is 
also associated with the presence of comorbidi‑
ties, estimated to affect 63% of individuals aged 
above 65 years and particularly common among 
patients with HF.14
Another important issue in the setting of HF 
is the chronic and debilitating course of the dis‑
ease that affects not only the heart but also oth‑
er organs. Available data show that populations 
with increased susceptibility to a more severe 
course include patients with cardiovascular dis‑
ease (mortality risk estimated at about 10%) and 
elderly individuals, particularly those above 80 
years (also reported to have high mortality rates). 
This indicates that patients with HF should be 
considered at high risk for severe SARS ‑CoV‑2 
infection and should be carefully monitored for 
any developing symptoms.
infections. Due to the growing number of pa‑
tients with SARS ‑CoV‑2 infection, the launch 
of the so called second ‑line infectious disease 
hospitals is planned in the near future. At the 
same time, isolation facilities are being creat‑
ed, which can accommodate patients with CO‑
VID‑19 with no or mild symptoms. Constantly 
updated information on the COVID‑19 pandem‑
ic in Poland, along with a list of infectious dis‑
ease hospitals, is available on the official web‑
site of the Ministry of Health (https://www.gov.
pl/web/koronawirus).
In the context of the COVID‑19 pandemic, 
the proper triage of patients before arriving at 
a healthcare facility is of particular importance. 
It seems that telemedicine should largely en‑
able an effective control of the patient as well 
as quick decision ‑making on isolation or quar‑
antine. Such an approach directly protects oth‑
er patients, medical personnel, and the commu‑
nity against the risk of contact with an infected 
person. Communication using smartphones and 
computers with a webcam is available 24 hours 
a day, 7 days a week. It enables the assessment 
of infectious and respiratory symptoms. More‑
over, healthcare professionals can obtain de‑
tailed information concerning travel, exposure, 
or contact with infected individuals. An opti‑
mal approach would be to include telemedicine 
systems in screening algorithms, hospital ad‑
mission process, and quarantine surveillance.2,3
Myocardial and vascular damage in the course 
of severe acute respiratory syndrome coro‑
navirus 2 infection The effect of SARS ‑CoV‑2 
on the human body is closely related to the mem‑
brane receptor angiotensin ‑converting enzyme 2 
(ACE2) and the renin–angiotensin–aldosterone 
(RAA) system. The transmembrane serine pro‑
tease TMPRSS2 aids active binding of viral enve‑
lope proteins to the host cell. The ACE2 expres‑
sion was identified in the cells of numerous or‑
gans (eg, oral cavity, colon, stomach, and gallblad‑
der), including also type II alveolar epithelial cells, 
and the lungs seem to be the main route of entry 
for SARS ‑CoV‑2.4 Moreover, the ACE2 expression 
was noted in vascular endothelial cells, cardio‑
myocytes, and the cells of other organs, includ‑
ing the kidneys, which increases the risk of mul‑
tiple organ damage.5 On contact with the virus, 
the ACE2 expression decreases, which leads to 
a local increase in angiotensin II levels (the main 
substrate for ACE2), thus promoting RAA system 
stimulation. The exact mechanism of myocardi‑
al and vascular damage due to SARS ‑CoV‑2 infec‑
tion is currently being studied, with a special em‑
phasis on the endothelium.6 Most of the available 
data were obtained during severe acute respiratory 
syndrome (SARS) and Middle East respiratory syn‑
drome (MERS) epidemics. By analogy to SARS ‑CoV, 
which has a similar genome to that of SARS ‑CoV‑2, 
it can be speculated that SARS ‑CoV‑2 causes direct 
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develop de novo HF in the acute stage of COV‑
ID‑19 is a major challenge, as dyspnea is common 
to both conditions. De novo HF in the course of 
COVID‑19 may be caused by acute myocardi‑
al inflammation, myocardial ischemia, Takot‑
subo syndrome, or arrhythmia. With severe re‑
spiratory infection / ARDS and hypoxia, due to 
COVID‑19, this mechanism of injury appears 
to be important.15 In a recent study including 
patients with COVID‑19, Wang et al10 reported 
acute cardiac injury in 7.2% of the cohort; shock, 
in 8.7%; and arrhythmia, in 16.7%. On the oth‑
er hand, Huang et al 11 reported that 12% of pa‑
tients developed acute cardiac injury with an in‑
crease in high ‑sensitivity troponin I levels and 
new abnormalities on electrocardiography and 
The WHO has defined the profile of a patient 
at greater risk of COVID‑19 by listing diseases 
and conditions associated with increased suscep‑
tibility. They include cardiovascular diseases (eg, 
hypertension, myocardial infarction, and stroke), 
diabetes, chronic respiratory diseases, and cancer.
Identification of patients at high risk for heart failure 
There are scarce clinical data on de novo HF in 
patients with COVID‑19, although the Chinese 
studies9-11 indicate 2 possible scenarios: 1) devel‑
opment of HF in the acute stage of COVID‑19, 
and 2) development of HF in COVID‑19 survivors.
De novo heart failure in the acute stage of coronavi-
rus disease 2019 Identification of patients who 
 FIGURE 1 Postulated mechanisms of acute cardiovascular injury caused by severe acute respiratory syndrome coronavirus 2
 ↑ – moderate elevation
 ↑↑ – severe elevation
 ↓ – moderate reduction
 ↓↓ – severe reduction
 Abbreviations: ACE2, angiotensin ‑converting enzyme 2; ACS, acute coronary syndrome; ARDS, acute respiratory distress syndrome; Ang II, angiotensin II; BNP, brain 
natriuretic peptide; CRP, C ‑reactive protein; LDH, lactate dehydrogenase; LV / RV, left ventricular / right ventricular; SARS ‑CoV‑2, severe acute respiratory syndrome 
coronavirus 2; TMPRSS2, transmembrane protease serine 2
1
Cell entry Lungs (type II alveolar epithelial cells), vascular endothelium, myocardium, intestinal epithelium, kidneys, Leydig cells
↑ ↑ Troponin, ↑ ↑ BNP, ↑ creatinine , renal dysfunction, myocardial dysfunction
   Acute myocarditis,  stress cardiomyopathy, ACS,  venous / arterial thrombosis
LV / RV acute heart failure, cardiogenic shock
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stage of COVID‑19 do not always indicate acute 
coronary syndrome (ACS).
De novo heart failure in coronavirus disease 2019 survivors 
Long ‑term data in the COVID‑19 population are 
lacking. However, it may be assumed that some 
survivors will develop HF by analogy to other vi‑
ral diseases. Helpful diagnostic tools to identify 
these patients include NT ‑proBNP measurement 
and standard imaging studies such as echocar‑
diography and cardiac magnetic resonance. Nov‑
el echocardiographic techniques, such as speck‑
le tracking longitudinal strain imaging, may also 
prove useful. Heart failure may be more likely to 
develop in patients with cardiovascular risk fac‑
tors as well as in elderly patients with comorbidi‑
ties who experienced severe COVID‑19 infection.
In COVID‑19 survivors, cardiac assessment 
with or without NT ‑proBNP measurement is in‑
dicated, optimally combined with echocardiog‑
raphy. In diagnostically uncertain cases, the as‑
sessment should also include cardiac magnetic 
resonance imaging, if feasible. The time frame 
for the assessment is difficult to determine and 
should depend on the patient’s clinical status. 
Currently, there are no data to support the tim‑
ing and frequency of cardiac workup for HF in 
patients who suffered from multiorgan failure 
in the course of COVID‑19.
The aim of cardiac assessment is to identify de 
novo HF in the following scenarios: 1) if the pa‑
tient presents with clinical symptoms (dyspnea, 
reduced exercise tolerance, fatigue, signs of fluid 
overload) regardless of the severity of COVID‑19, 
and 2) in all patients who recovered from stage 
3 of COVID‑19 (multiorgan failure), with a par‑
ticular emphasis on the evaluation of the right 
ventricle and pulmonary artery pressure.
It is difficult to clearly determine the extent 
of cardiac diagnostic workup in the remaining 
patients with a history of SARS ‑CoV‑2 infection.
Based on data regarding the prognosis of pa‑
tients with a history of pneumococcal pneu‑
monia (an increase in the mortality rate over 
the next 10 years)20 as well as increased cardio‑
vascular risk in those with a history of SARS, 
long ‑term cardiovascular follow ‑up seems to 
be also important in the group of patients with 
COVID‑19.
Patients with heart failure and coronavirus 
disease 2019 Treatment with renin –angioten-
sin–aldosterone system inhibitors Angiotensin‑
‑converting enzyme inhibitors (ACEIs; or 
angiotensin ‑receptor blockers [ARBs] in case of 
ACEI intolerance), angiotensin receptor–neprily‑
sin inhibitors, and mineralocorticoid receptor in‑
hibitors constitute the cornerstone of HF thera‑
py as drugs that block the RAA system. There is 
solid evidence for their beneficial effects in terms 
of reducing hospitalization and mortality rates in 
patients with HF.21 Moreover, discontinuation of 
echocardiography. In a study by Chen et al,16 
including 120 patients with COVID‑19, elevat‑
ed levels of NT ‑proBNP were noted in 27.5% of 
the population, and of cardiac troponin, in 10%. 
However, no data were reported on the percent‑
age of patients who developed HF symptoms or 
on the time of symptom onset. Moreover, el‑
evated troponin levels may be also related to 
multiple organ damage in the course of COV‑
ID‑19. A rise in troponin levels was associat‑
ed with a 4‑fold higher risk of in ‑hospital mor‑
tality (hazard ratio, 4.26; 95% CI, 1.92–9.49).17
De novo HF may develop at different stages 
of COVID‑19, depending on etiology. However, it 
most often occurs in the third stage of acute dis‑
ease (FIGURE 2), which is characterized by multiorgan 
failure associated with an enhanced immune re‑
sponse, with the predominant role of IL‑6. Mul‑
tiorgan failure affects around 5% of patients with 
COVID‑19. Zhou et al 18 reported HF as a compli‑
cation of COVID‑19 in 23% of the patients, more 
often in those who died than in survivors (51.9% 
vs 11.7%).18 In patients with COVID‑19, ARDS may 
also manifest with right ‑sided HF associated with 
pulmonary hypertension.15 Hu et al 19 reported 
a case of acute HF in the course of fulminant myo‑
carditis in a 37‑year ‑old man without comorbid‑
ities, who presented with elevated levels of high‑
‑sensitivity troponin T and NT ‑proBNP and re‑
duced left ventricular ejection fraction (27%). Clin‑
ical and echocardiographic improvement as well 
as a reduction in the levels of inflammatory mark‑
ers were achieved with methylprednisolone and 
immunoglobulin. However, no data on long ‑term 
follow ‑up of this patient have been published.
The measurement of NT ‑proBNP and tropo‑
nin levels in acute COVID‑19 should be combined 
with the clinical, electrocardiographic, and echo‑
cardiographic (preferably point ‑of ‑care ultra‑
sonography) assessment of the patient. Elevat‑
ed high ‑sensitivity troponin levels in the acute 
2
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Infl ammatory markers
SARS-CoV-2 infection – phases
SARS‑CoV‑2 
infection Host reaction
5–10 / 14 days
Lung involvement
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Cardiac involvement 
– biomarkers
FIGURE 2 Stages of severe acute respiratory syndrome coronavirus 2 infection
 Abbreviations: see FIGURE 1
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to protein expression and the functionality of 
the receptor.
No correlation between the level of the ACE2 
expression and the severity of infection was re‑
ported. Another important consideration is that 
the gene encoding ACE2 is located on the X chro‑
mosome, which means that men have 1 copy 
whereas women have 2 copies of the encoding 
gene. However, this was not shown to correlate 
with an increased incidence of COVID‑19 among 
women. Finally, it is important to note that the 
ACE2 expression decreases with age.29
Currently, there is an ongoing pilot trial of 
soluble recombinant human ACE2 (APN01) in 
the treatment of patients with COVID‑19.30 It is 
hypothesized that this therapy may use the dual 
function of ACE2: 1) as a virus receptor to reduce 
the viral load, and 2) as an RAA system regulator 
to reduce the deleterious effects of angiotensin II.30
On the other hand, it is important to consid‑
er the proven beneficial effects of RAA system 
inhibitors on the cellular level (FIGURE 3). These 
effects are also crucial in the treatment of lung 
diseases. Lung epithelial cells contain angioten‑
sin II receptor type 1 (AT1) and 2 (AT2), which 
makes the lungs susceptible to the effects of 
angiotensin II and angiotensin (1–7). Available 
evidence indicates that the RAA system plays 
an important role in the pathophysiology of lung 
disease. Inhibition of the AT1 receptor by us‑
ing ARBs leads to a reduction in the inflamma‑
tory response, proliferation, and fibrosis (by 
reduced stimulation of the AT1‑receptor sig‑
naling pathway). The use of ACEIs leads to re‑
duced synthesis of angiotensin II by blocking 
HF therapy was shown to lead to rapid clinical de‑
terioration (within several days or weeks) as well 
as an increase in long ‑term mortality.22 Except an‑
giotensin receptor–neprilysin inhibitors, renin in‑
hibitors are the mainstay of standard therapy for 
hypertension or coronary artery disease. Recent‑
ly, it was shown that shortly after withdrawal of 
some forms of valsartan from the market, there 
was a significant increase in the rate of emergen‑
cy admissions and hospitalizations due to stroke 
and transient ischemic attack.23 Moreover, the use 
of ACEIs or ARBs in patients with hypertension 
who were hospitalized due to COVID‑19 was as‑
sociated with a lower risk of all ‑cause mortality.24
Recently, Sommerstain and Grani25 have put 
forward a hypothesis that the use of ACEIs leads 
to upregulation of the ACE2 expression, which 
may increase the individual’s susceptibility to 
SARS ‑CoV‑2 infection. In fact, ACE2 was iden‑
tified as the functional receptor for SARS ‑CoV‑2 
by showing that ACE2‑positive cells were more 
susceptible to viral infection. However, the in‑
fection is also possible in ACE2‑negative cells, 
which suggests the presence of an additional 
route of entry.26 Moreover, reliable data indi‑
cating that the use of ACEIs or ARBs leads to 
upregulation in the ACE2 expression are lack‑
ing, and the available studies are not convinc‑
ing or even contradictory. While some authors 
confirm the link between drug administration 
and upregulation of the ACE2 expression,27 oth‑
ers do not report such an association.28 In addi‑
tion, this was experimental research using ani‑
mal or cellular models and it assessed the mRNA 
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– Oxidative stress reduction 
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 FIGURE 3 The physiological function of the renin–angiotensin–aldosterone system
 Abbreviations: ACE, angiotensin ‑converting enzyme; ACEI, angiotensin ‑converting enzyme inhibitors; ARB, angiotensin ‑receptor blockers; APP, aminopeptidase P; 
AT1, angiotensin II receptor type 1; AT2, angiotensin II receptor type 2; DPP‑4, dipeptidyl peptidase 4; NEP, neutral endopeptidase; NO nitric oxide; 
PG, prostaglandin; others, see FIGURE 1
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10%.1,17,36 Mechanical ventilation is recommend‑
ed in patients with moderate (the ratio of par‑
tial pressure of arterial oxygen normalized to 
the fraction of inspired oxygen [PaO2 / FiO2], 100–
200) or severe (PaO2 / FiO2 <100) ARDS with hy‑
poxemia or symptoms despite oxygen supplemen‑
tation.37 Lung ‑protective mechanical ventilation 
with a target tidal volume of (usually) 6 ml/kg of 
predicted body weight and target plateau airway 
pressure of 30 cm H2O or lower is recommended.
37 
Permissive respiratory acidosis in lung ‑protective 
mechanical ventilation should be kept at a pH 
level of 7.25 or higher. Permissive hypoxemia 
with a PaO2 of 55 to 80 mm Hg or oxygen satu‑
ration of 88% to 95% can also be considered.37 In 
patients with ARDS with a PaO2  / FiO2 of 150 or 
lower, prone positioning should be considered.37 
Noninvasive interventions such as noninvasive 
positive pressure ventilation and high ‑flow na‑
sal cannula should be used with great caution due 
to the risk of viral transmission.38 The value of 
positive end ‑expiratory airway pressure (PEEP) 
should be adjusted to the cardiovascular status 
(in patients with heart failure, especially in those 
in whom cardiac output depends on appropriate 
preload, higher PEEP values should be avoided or 
applied with caution) (FIGURE 4). For further useful 
information, see Supplementary material.
Extracorporeal membrane oxygenation Severe respi‑
ratory failure is reported in approximately 10% of 
patients with SARS ‑CoV‑2 infection. Venovenous 
extracorporeal membrane oxygenation (ECMO) 
should be considered if any of the following crite‑
ria are met after 72 hours of mechanical ventila‑
tion: 1) PaO2 / FiO2 <80 mm Hg (regardless of the 
PEEP level); 2) plateau airway pressure ≤30 mm Hg 
and partial pressure of carbon dioxide >55 mm Hg; 
3) presence of pneumothorax, air leak exceeding 
one ‑third of tidal volume, duration longer than 48 
hours; 4) circulation deterioration, norepineph‑
rine dosage >1 μg / (kg × min); 5) cardiopulmo‑
nary resuscitation.
Early awake ECMO can also be considered in 
patients who have been supported by mechani‑
cal ventilation with high ventilator settings for 
over 7 days and who meet the necessary condi‑
tions for awake ECMO.39
The use of ECMO is based on the experience of 
single centers, and convincing data on its appli‑
cation in patients with COVID‑19 are lacking. As 
SARS ‑CoV‑2 infection causes a cytokine storm, 
the use of ECMO may aggravate the storm and 
induce further endothelial dysfunction, leading 
to multiorgan failure.
The use of hemoperfusion was reported in 
a single study. It was shown that hemoperfu‑
sion might reduce cytokine load and, at least 
to some extent, restore immune homeostasis.40
In patients with COVID‑19 without severe re‑
spiratory failure yet with severe cardiovascu‑
lar complications leading to cardiogenic shock, 
the angiotensin ‑converting enzyme (ACE). This, 
similarly to ARBs, downregulates AT1 receptor 
activity, but additionally activates the ACE2 / an‑
giotensin (1–7) pathway, which reduces fibrosis, 
inflammatory response, and apoptosis. More‑
over, ACE inhibition also accounts for reduced 
bradykinin degradation, which leads to a high‑
er release of the endothelium ‑derived relaxing 
factor such as nitric oxide and prostanoids.31,32
Considering the above data and the most re‑
cent position statements of the Polish Cardiac 
Society as well as the European Society of Car‑
diology / American Heart Association / American 
College of Cardiology, COVID‑19 patients with 
cardiovascular disease, including HF, should 
continue therapy with RAA system inhibitors 
or the therapy should be started as planned in 
newly diagnosed patients.33
Heart failure exacerbation in patients with coro-
navirus disease 2019 Pharmacologic treatment In 
patients with HF, it is particularly important to 
maintain the proper level of body fluids to en‑
sure adequate organ perfusion. However, exces‑
sive fluid therapy may exacerbate hypoxemia in 
patients with COVID‑19. Therefore, to reduce 
pulmonary exudate and improve oxygenation, 
balanced fluid therapy for adequate tissue per‑
fusion should be provided.34 In patients without 
tissue hypoperfusion, the use of conservative 
fluid management is associated with a shorter 
duration of mechanical ventilation and length 
of intensive care unit (ICU) stay.34
In the case of shock (especially septic shock), 
careful fluid management is recommended to 
avoid fluid overload. If symptoms persist despite 
optimal fluid therapy, the mean arterial pressure 
(MAP) is lower than 65 mm Hg, and no improve‑
ment of perfusion has been achieved, the use 
of vasopressor agents is recommended. Norepi‑
nephrine is the first ‑line treatment, while adren‑
aline and vasopressin may be additionally used to 
achieve optimal MAP. If symptoms of hypoperfu‑
sion and myocardial dysfunction persist despite 
achieving target MAP, positive inotropic therapy 
with dobutamine should be considered. However, 
due to the risk of tachycardia, dopamine should 
be used with caution and only in patients with 
bradycardia or at low risk of tachycardia. In pa‑
tients older than 65 years, the MAP value of 60 
to 65 mm Hg can be considered as a therapeu‑
tic target. The use of antithrombotic prophylax‑
is (preferably with low ‑molecular ‑weight hepa‑
rin or with subcutaneous unfractionated hepa‑
rin at a dose of 5000 units twice daily) is recom‑
mended in patients without contraindications. If 
contraindications are present, intermittent pneu‑
matic compression should be used.35
Mechanical ventilation Oxygen therapy is used 
in 40% to 75% of patients with SARS ‑CoV‑2 in‑
fection, while mechanical ventilation, in 6% to 
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far. The frequent occurrence of arrhythmia can 
be partly attributed to metabolic disorders, myo‑
cardial hypoxia, and inflammatory processes 
in the course of viral infection in patients with 
and without a history of cardiovascular disease. 
New ‑onset malignant tachyarrhythmia in pa‑
tients with elevated troponin levels should raise 
a suspicion of underlying myocarditis.16,42 An‑
other issue that raises concern is the possible 
iatrogenic damage to the heart caused by drug 
therapy for COVID‑19, especially when antivi‑
ral drugs,10 chloroquine (CQ), or azithromycin 
are used (see the Treatment of coronavirus dis‑
ease 2019 section).
It is extremely important to monitor elec‑
trocardiographic and electrolyte disorders (hy‑
pokalemia and hypomagnesemia may increase 
the risk of QTc prolongation and torsade de 
pointes) in patients treated for COVID‑19.
The  Working Group on Heart Rhythm of 
the Polish Cardiac Society has published an an‑
nouncement on their website regarding the check‑
up of cardiac implantable electronic devices (pace‑
makers, cardiac resynchronization therapy pace‑
makers, implantable cardioverter‑defibrillators, 
and cardiac resynchronization therapy defibrilla‑
tors) during the COVID‑19 epidemic in the gener‑
al population, individuals under quarantine, and 






Acute coronary syndrome as the cause of heart fail-
ure exacerbation Severe acute respiratory syn‑
drome coronavirus 2 can cause ACS among oth‑
er cardiovascular complications, but most of 
the available data come from observations of 
real ‑world populations treated for the infection 
and have not been confirmed by scientific evi‑
dence.43,44 In a study including 75 hospitalized 
patients diagnosed with COVID‑19, acute myo‑
cardial infarction accounted for 2 deaths among 
5 fatal cases.43
Patients with ACS and SARS ‑CoV‑2 infection 
often have poor prognosis. This is because pa‑
tients with ACS develop myocardial ischemia 
or necrosis, which further reduces the func‑
tional reserve of the heart. Therefore, patients 
with SARS ‑CoV‑2 infection are more likely to 
develop HF, which leads to a sudden deterio‑
ration of the clinical status. In the Wuhan pa‑
tient population, a history of ACS was associat‑
ed with a more severe disease course and high 
mortality rates. In patients with HF of ischemic 
etiology, SARS ‑CoV‑2 infection may be a risk 
factor for rapid clinical deterioration, severe 
disease course, and death.45 Another reason is 
the possible delay in elective invasive procedures, 
which may directly affect the patient’s prognosis. 
venoarterial ECMO should be considered. For 
further useful information, see Supplementa‑
ry material.
Arrhythmia Cardiac arrhythmia is common in 
patients with COVID‑19 infection. In a group 
of 137 patients admitted to the hospital due to 
COVID‑19, nonspecific palpitations were found 
in 7.3% of cases.41 In another study, in hospital‑
ized patients with COVID‑19, arrhythmia was 
reported in 16.7%, and it was more common 
among patients staying in the ICU than outside 
the ICU (44.4% vs 6.9%).10 However, no data on 
the types of arrhythmia have been published so 
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Oxygen therapy– Target SpO2: 92%–96%
– Careful monitoring of the patient
– Endotracheal intubation 
– Intubation by the most experienced provider
– Personal protective equipment (N95, PAPR)  
– Limiting the number of people
Initial lung-protective mechanical ventilation settings
– Tidal volume: 4–8 ml/kg of predicted body weight
– Pplateau ≤30 cm H2O
– Initial PEEP ≥5–8 cm H2O 
– Respiratory rate: set to preintubation values (usually 16–24 breaths per minute)
Setting reassessment and modifi cation
– Goals: pH ≥7.25; PaO2, 55–80 mm Hg, SpO2, 92%–96%; Pplateau <30 mm Hg
– Decrease FiO2 to target SpO2: 92%–96%
– Set PEEP values based on Fi02 (reference AROS net table)
– If Pplateau <30 cm H2O, consider decreasing tidal volume or PEEP
Patients with mild or no ARDS
– Frequent reassessment of ventilator 
settings to achieve above targets
– Minimize fl uid administration
– Continue supportive care
Patients with moderate or severe ARDS
– Pulmonary consultation
– Consider adjunctive therapy, including 
but not limited to:
 · higher PEEP strategy
 · neuromuscular blocade
 · prone position ventilation 
 (12–16 hrs)
 · VV‑ECMO











 FIGURE 4 Ventilation strategy in coronavirus disease 2019. Based on Zhang et al87
 a Use with extreme caution; deterioration or no improvement within 1 hour is an indication for 
intubation.
 Abbreviations: AHF, acute heart failure; COVID‑19, coronavirus disease 19; FiO2, fraction of inspired 
oxygen; HF, heart failure; HFNC, high ‑flow nasal cannula; NIPPV, noninvasive positive pressure 
ventilation; PaO2, partial pressure of oxygen in the blood; PAPR, powered air ‑purifying respirator; PEEP, 
positive end ‑expiratory pressure; Pplateau, plateau airway pressure; SpO2, peripheral capillary oxygen 
saturation; VV ‑ECMO, venovenous extracorporeal membrane oxygenation; others, see FIGURE 1
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that the increase in troponin concentrations is 
not always due to ischemic myocardial injury, 
which indicates the need for an individualized 
approach to management. In each individual pa‑
tient, the results of biochemical tests are the net 
effect of the following: 1) the status and func‑
tional reserve of the organs at baseline; 2) sever‑
ity of the systemic inflammatory response to in‑
fection; 3) the impact of the virus itself on var‑
ious organs; 4) the consequences of multiorgan 
dysfunction due to virus activity and systemic 
inflammatory response.
The most frequent laboratory abnormalities in 
the course of COVID‑19 are summarized in TABLE 1. 
These abnormalities indicate that, apart from 
progressive respiratory failure, the most com‑
mon causes of unsuccessful therapy are acute HF 
in the course of ACS, fulminant myocarditis, Ta‑
kotsubo syndrome, acute kidney and liver fail‑
ure, and sepsis. Coagulation disorders are also 
associated with severe disease course.
The most common biochemical abnormali‑
ties indicate an uncontrolled severe inflamma‑
tory response with a cytokine storm, with in‑
creased blood levels of interleukins (IL‑1 and 
IL‑6), granulocyte colony ‑stimulating factor, in‑
terferon γ, tumor necrosis factor α, monocyte 
chemotactic protein 1, and others.11 The cyto‑
kine storm is considered to be the major cause 
of multiorgan failure, secondary bone marrow 
suppression, and additional bacterial superin‑
fections responsible for sepsis. On laboratory 
testing, this manifests as hypoalbuminemia 
as well as increased ferritin and procalcitonin 
levels. Cytokine storm is diagnosed in 3% to 
4% of patients with viral sepsis and is associ‑
ated with unfavorable prognosis. A useful tool 
for predicting cytokine storm is HScore, which 
has a sensitivity of 93% and specificity of 87%.48 
It can be calculated using an online calculator 
(http://saintantoine.aphp.fr/score/).
The role of echocardiography Echocardiography 
has a significant role in patients with HF and 
those with a complicated course of COVID‑19. It 
helps determine the cause of dyspnea (respirato‑
ry failure or HF) and, in combination with clin‑
ical data, guides therapeutic decision ‑making. 
It is especially important in patients with con‑
current pneumonia and myocarditis caused by 
SARS ‑CoV‑2, as it allows for identification of pa‑
tients at highest risk.
The examination should be performed at bed‑
side and over the shortest possible time, without 
recording parameters that do not affect thera‑
peutic decisions but including those that reflect 
basic cardiac function (ventricular size and con‑
tractility, hemodynamically significant valvular 
defects, pericardial effusion, inferior vena cava 
width, and others). Personal protective equip‑
ment should be used. If possible, the examina‑
tion should be performed by a team of treating 
An algorithm has been developed for the man‑
agement of patients with ST ‑segment elevation 
myocardial infarction, who require prompt re‑
perfusion treatment, in the era of the coronavi‑
rus pandemic. In order not to delay reperfusion, 
the algorithm also includes fibrinolytic therapy.46
The principles of management in patients with 
ACS can be found on the website of the Associa‑
tion of Cardiovascular Interventions of the Pol‑
ish Cardiac Society (Supplementary material).
The role of selected biomarkers There is ongo‑
ing research and discussion regarding the im‑
portance of assessing the markers of myocardi‑
al injury, inflammation, and thrombosis in pa‑
tients with SARS ‑CoV‑2 infection with a histo‑
ry of cardiovascular disease. The significance 
of myocardial injury, defined as cardiac tropo‑
nin levels above the 99th percentile of the up‑
per reference limit, independently of new elec‑
trocardiographic and echocardiographic abnor‑
malities, in patients with SARS ‑CoV‑2 infec‑
tion has been emphasized. In a study by Shi 
et al,17 increased levels of the cardiac marker, 
troponin, were reported in 19.7% of hospital‑
ized SARS ‑CoV‑2‑positive patients.17 These pa‑
tients had a significantly higher in ‑hospital mor‑
tality compared with those without cardiac in‑
jury (51.2% vs 4.5%). Moreover, a positive corre‑
lation was observed between the levels of high‑
‑sensitivity troponin I and mortality.17 Of note, 
patients with elevated troponin levels were old‑
er and more often had cardiovascular comor‑
bidities than those without cardiac injury (hy‑
pertension, 59.8% vs 23.4%; diabetes, 24.4% 
vs 12%; ischemic heart disease, 29.3% vs 6%; 
cerebrovascular disease, 15.9% vs 2.7%; and HF, 
14.6% vs 1.5%).17 Guo et al9 reported an associ‑
ation between troponin levels and the prog‑
nosis of patients with cardiovascular disease. 
Increased levels of high ‑sensitivity troponin 
T were correlated with higher mortality com‑
pared with the group with normal troponin lev‑
els (69.4% vs 13.3%). Moreover, normal tropo‑
nin levels were associated with better progno‑
sis in patients without cardiovascular disease 
(mortality rate, 7.6%).9 Zhou et al 18 observed 
2 patterns of troponin dynamics. In the most 
common clinical presentation with pulmonary 
involvement, elevated troponin levels at base‑
line that further increased throughout the clin‑
ical course were associated with a higher risk of 
death compared with patients with elevated yet 
stable troponin levels.18 In patients with domi‑
nant cardiac involvement (much less common), 
troponin concentrations, which were significant‑
ly increased at baseline, decreased after cardio‑
vascular support (including ECMO), which cor‑
related with clinical improvement. This may 
suggest SARS ‑CoV‑2‑induced myocarditis.19,47
An important consideration in patients un‑
dergoing diagnostic workup for COVID‑19 is 
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Echocardiography should be limited to hospi‑
talized patients with suspected cardiac causes 
of clinical deterioration. It is not recommend‑
ed to perform echocardiography as a routine 
examination in all patients with COVID‑19 
or to perform repeat echocardiography with‑
out clear indications resulting from clinical 
deterioration.
Echocardiography can also be used to mon‑
itor fluid supply in patients with shock or dur‑
ing ECMO. Transesophageal echocardiography 
is an aerosol ‑generating procedure and requires 
personal protective equipment, similarly to, for 
example, intubation or bronchoscopy. Therefore, 
this type of echocardiography should be used 
only if absolutely necessary.
physicians. Portable devices are preferable, ded‑
icated for use in the infection zone, easy to dis‑
infect, and enabling archiving and consulting 
of images.10,15,19,39, 49-52
The examination can be extended to include 
pulmonary and pleural ultrasound, and, if indi‑
cated, abdominal ultrasound, to take full advan‑
tage of ultrasound capabilities and avoid addi‑
tional exposure of the staff. The severity of le‑
sions in the lung tissue can be assessed based 
on the presence and number of B ‑line artifacts 
(they may also occur in HF), as well as the pres‑
ence of a thickened or irregular pleural line and 
consolidated lung tissue.53-55 Fluid in the serous 
cavities is not a typical finding in patients with 
COVID‑19.
TABLE 1 The most frequent laboratory abnormalities in patients with coronavirus disease 2019
Abnormality Suspected cause Relationship with more severe clinical course, need 
for intensive care unit stay, or prognosis of death 
(references)
Lymphocytes ↓ Inflammatory activation / cytokine storm Wang et al,10 Zhang et al,88 Chen et al,89 Xu et al,90 
Liu et al,91 Wang et al,92 Chen et al,93 Chen et al,94 + meta‑
‑analysis (P <0.001) by Rodriguez‑Morales et al95
Albumin ↓ Meta ‑analysis (P <0.001) by Rodriguez‑Morales et al95
Ferritin ↑ Chen et al89
CRP ↑ Meta ‑analysis (P <0.001) by Rodriguez‑Morales et al95
White blood cells ↓ Meta ‑analysis (P <0.001) by Rodriguez‑Morales et al95
Red blood cells ↓ Chen et al,89 Chen et al93
Urinary protein ↑, red blood cells ↑ Li et al,96 Cheng et al97
White blood cells ↑ Secondary bacterial infection Wang et al,10 Zhang et al,88 Chen et al,89 Xu et al,90 
Liu et al,91 Wang et al,92 Chen et al,93 Chen et al,94 + meta‑
‑analysis (P <0.001) by Rodriguez‑Morales et al95
Neutrophils ↑ Chen et al,89 Liu et al,91 Wang et al92
Procalcitonin ↑ Wang et al,10 Zhang et al,88 Chen et al,89 Xu et al,90 
Liu et al,91 Wang et al92
LDH ↑, ALT ↑, AST ↑, bilirubin ↑ Secondary liver damage – multiorgan failure Meta ‑analysis of 2 studies (AST, P = 0.427; ALT, P = 0.186; 
bilirubin, P = 0.004); meta ‑analysis of 3 studies (AST, 
P = 0.427); meta ‑analysis of 5 studies (LDH, P <0.001) by 
Rodriguez‑Morales et al95
Creatinine ↑, glomerular filtration 
rate ↓, urea ↑
Secondary kidney damage – multiorgan failure Creatinine and glomerular filtration rate (Chen et al,89 
Li et al,96 Cheng et al97) + meta ‑analysis by 
Rodriguez‑Morales et al95 (P = 0.328), urea (Li et al,96 
Cheng et al97)
Potassium ↓ RAAS activation Chen et al98
Troponin ↑ Myocardial injury Meta ‑analysis by Lippi et al99
NT ‑proBNP ↑ Increased myocardial wall tension Shi et al17
D ‑dimer ↑ Inflammatory activation / cytokine storm
Systemic coagulopathy / DIC
Zhang et al,88 Chen et al,89 Wang et al92
Prothrombin time ↑ Shi et al17
Platelet count ↓ Meta ‑analysis by Lippi et al100
↑ – Increase
↓ – Decrease
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; DIC, disseminated intravascular coagulation; NT ‑proBNP, N ‑terminal fragment of the prohormone 
brain natriuretic peptide; RAAS, renin–angiotensin–aldosterone system; others, see FIGURE 1
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some immunosuppressive drugs (eg, mycophe‑
nolate mofetil or azathioprine) may be tempo‑
rarily discontinued (with close monitoring of 
possible rejection).57
At present, decisions regarding HTx or LVAD 
implantation are particularly challenging, not 
only due to the risk of SARS ‑CoV‑2 infection 
in the donor and recipient but also because of 
the enormous burden of the pandemic on health‑
care facilities. Although the leading societies 
agree that HTx surgeries should not be paused in 
the coronavirus era, there is ongoing discussion 
about the safety of the procedure in the face of 
possible donor and recipient infection (eg, there 
have been 3 updates of the Poltransplant posi‑
tion statement in March 2020).56-58 Although 
SARS ‑CoV‑2 transmission from the donor to re‑
cipient has not yet been confirmed, this is highly 
probable in the case of donor infection. For this 
reason, every effort must be made to achieve 
2 goals at the same time: 1) a definitive exclu‑
sion of donor SARS ‑CoV‑2 infection, and 2) ex‑
clusion of the infection in the recipient (as soon 
as possible, but in some urgent HTx cases, the re‑
sult may be available only after the transplant).
According to the latest recommendations of 
Poltransplant and the ISHLT, SARS ‑CoV‑2 in‑
fection should be excluded in every potential 
donor (using a real ‑time polymerase chain re‑
action [RT ‑PCR] test).57,58 Similarly, although 
there is some controversy, Poltransplant rec‑
ommends that all recipients should be tested for 
SARS ‑CoV‑2, regardless of the presence of clini‑
cal symptoms. Standard RT ‑PCR swab testing is 
recommended both in the donor and the recip‑
ient.57,58 However, given the possibility of false‑
‑negative results (especially in the case of re‑
cent infection), chest computed tomography is 
also recommended in donors and recipients, be‑
cause it may show early signs of SARS ‑CoV‑2 in‑
fection even before symptom onset or positive 
RT ‑PCR test results.57,58
The ISHLT guidance suggests that the treat‑
ment should be individualized, especially in pa‑
tients with the INTERMACS (Interagency Reg‑
istry for Mechanically Assisted Circulatory Sup‑
port) status 1–3, who were assessed as ineligi‑
ble for HTx but are considered for LVAD implan‑
tation. It seems that consideration of patients 
with better clinical condition (higher INTER‑
MACS status) for LVAD implantation may be 
temporarily postponed.57
As the epidemiological situation is constant‑
ly changing and clinicians gain increasing expe‑
rience, the recommendations on HTx and LVAD 
implantation are updated on a regular basis and 
can be found on the Poltrnasplant website.58
Treatment of coronavirus disease 2019 Effica-
cy and safety of new therapies The following data 
on COVID‑19 treatment come from the liter‑
ature published until the end of April 2020, 
In the era of the COVID‑19 pandemic, there is 
always uncertainty about the infectious status 
of the physician and the patient. Therefore, any 
elective tests should be postponed in patients 
who can be treated based on previous findings. 
However, the examination may be justified in 
the case of clinical deterioration or if there is 
a suspicion that echocardiographic findings will 
influence diagnostic and / or therapeutic deci‑
sion making (also in stable patients). In such cas‑
es, the examination should be performed after 
collecting an epidemiological history and with 
the use of face masks (at least surgical) both by 
the patient and the physician.49,50
Detailed recommendations of the Working 
Group on Echocardiography of the Polish Car‑
diac Society by Gackowski et al50 can be found 
at https://www.mp.pl/kardiologiapolska/issue/
article/15265.
Heart transplant and mechanical circulato‑
ry support The rapid spread of the COVID‑19 
pandemic has changed every aspect of medicine, 
including the work of heart transplant (HTx) 
centers, in an unprecedented manner.56 In our 
opinion, despite the lack of unequivocal evi‑
dence, it can be assumed that all patients with 
end ‑stage HF, history of HTx, left ventricular 
assist device (LVAD), or those who are awaiting 
HTx or LVAD implantation are at high risk of 
SARS ‑CoV‑2 infection and severe disease course. 
Therefore, physicians are now facing 2 challeng‑
es: the management of patients after HTx or 
LVAD implantation and of those who are await‑
ing the procedure.56
Currently, it is recommended to minimize 
the number of standard visits to medical fa‑
cilities, including visits to transplant centers 
in patients after HTx and LVAD, depending on 
the clinical status.57 Elective tests, including 
heart biopsies, should be postponed in select‑
ed cases. Although immunocompromised pa‑
tients are probably at higher risk of SARS ‑CoV‑2 
infection, prior immunosuppressive therapy 
should be continued.57 According to the recent 
guidelines of the International Society of Heart 
and Lung Transplantation (ISHLT), patients af‑
ter HTx or LVAD implantation with confirmed 
COVID‑19 should be stratified depending on 
the severity of symptoms into groups with mild, 
moderate, and severe infection.57 Patients with 
mild symptoms (without dyspnea or hypoxia) 
should be treated like any other patient. Patients 
with moderate (dyspnea, hypoxia requiring ad‑
ditional oxygen supply via the nasal cannula) 
and severe (need for ventilatory support due 
to ARDS, exacerbation of HF, or acute kidney 
failure) symptoms should be hospitalized, in‑
cluding the ICU stay. In these patients, specific 
therapy for COVID‑19 should be started imme‑
diately, with mechanical circulatory and respi‑
ratory support as necessary (eg, ECMO), while 
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and prevention of this parasitic disease.68 It has 
also been used as a self ‑medication by travelers; 
hence, its safety level seems to be high. The drug 
is also considered to be safe during pregnancy 
and in children, with only minor (and almost 
always mild to moderate) adverse effects such 
as headache, malaise, nausea and / or vomit‑
ing, blurred vision, itching, dizziness, concen‑
tration difficulties, and stomach symptoms.68,69 
Severe adverse effects of CQ, such as neuromy‑
opathy, retinopathy, or idiosyncratic reactions, 
are rare and usually associated with long ther‑
apy duration.
The concern about the cardiovascular adverse 
effects of CQ seems to be related to its chemical 
(structural) similarity to quinidine (both sub‑
stances are quinoline derivatives), an old anti‑
arrhythmic drug that may prolong the QT inter‑
val (so called quinidine effect), which is associat‑
ed with the risk of life ‑threatening polymorphic 
ventricular tachycardia (torsade de pointes).70 
However, it is likely that this well ‑known ar‑
rhythmogenic cardiotoxicity of quinidine should 
not be directly applied also to CQ.70 The cardio‑
vascular toxicity of oral CQ at an antimalari‑
al dose appears to be of minor importance, be‑
cause it rarely causes conduction disturbances 
and only slightly widens the QRS complex and 
prolongs the QT interval.70
Recommendations for physicians On March 13, 
2020, the President of the Office for Registra‑
tion of Medicinal Products, Medical Devices, 
and Biocidal Products in Poland issued a deci‑
sion regarding changes in the marketing permis‑
sion status for the Arechin (CQ phosphate) me‑
dicinal product. As a result, the following new 
therapeutic indication was added: “Supportive 
therapy in infections with Betacoronavirus such 
as SARS ‑CoV, MERS ‑CoV, and SARS ‑CoV‑2” (and 
related drug dosing).
There are several ongoing randomized clini‑
cal trials investigating the use of CQ or HCQ in 
the therapy and / or prevention of COVID‑19 (for 
more details, see the ClinicalTrials.gov website), 
including 1 Polish study (QUARANTINE2020 
[Chloroquine as Antiviral Treatment in Corona‑
virus Infection 2020], NCT04331600).
Several practical issues should be discussed in 
this context. It is generally believed that most in‑
dividuals with acquired (drug ‑induced) QT pro‑
longation will never develop torsade de pointes 
and that numerous patients with ventricular ar‑
rhythmia have a normal QT interval shortly be‑
fore the onset of arrhythmia.71 For epidemiolog‑
ical and logistical reasons, even baseline electro‑
cardiography, used to record the QT interval be‑
fore treatment, will be problematic in hospitals 
dedicated for patients with COVID‑19. Therefore, 
the focus should be placed on collecting an ex‑
tensive medical history of potential arrhythmic 
events both from the patient or his or her family 
mostly small nonrandomized clinical trials. 
Numerous studies are currently underway and 
the results has not been available yet.
Important questions are now being asked 
about the causal treatment of the disease and 
whether there are drugs that can improve out‑
comes in the most severe cases of COVID‑19, 
often requiring intensive care and mechanical 
ventilation. So far, no evidence ‑based data have 
been published to support the efficacy of any an‑
tiviral or immunomodulatory drugs in the treat‑
ment or prevention of COVID‑19 (including pro‑
phylaxis among medical personnel). Two groups 
of drugs seem to be effective therapeutic options 
in COVID‑19: 1) classic antiviral drugs interfer‑
ing with the spread or replication of pathogens, 
and 2) compounds that inhibit host inflamma‑
tory responses, particularly (and perhaps selec‑
tively) in the respiratory tract (cytokine inhibi‑
tors and specific antibodies).59 Quinoline deriva‑
tives such as CQ and hydroxychloroquine (HCQ) 
seem to be particularly promising.60
Chloroquine was shown to exert antiviral ef‑
fects against coronavirus in vitro by increasing 
endosomal pH (which hinders fusion between 
the virus and the target cell) and interfering 
with the glycosylation of virus cell receptors.61 
However, there are limited clinical and exper‑
imental data suggesting that CQ may provide 
clinical benefits in SARS ‑CoV‑2 infection.59,62,63 
Already 15 years ago, it was reported that CQ 
has antiviral activity against SARS ‑CoV‑1 in 
vitro.64 Similar observations were reported for 
SARS ‑CoV‑2. Wang et al65 revealed that CQ ef‑
fectively inhibit SARS ‑CoV‑2 infection in Vero 
E6 cell cultures even at low micromolar concen‑
trations (which are therefore achievable in, for 
example, human lung tissue).65 Consistent re‑
sults were presented by Yao et al,66 who showed 
that both CQ and HCQ reduce the activity or 
replication of coronaviruses in in ‑vitro cell cul‑
tures. In addition, a small French nonrandom‑
ized open ‑label trial has been published recent‑
ly,67 in which HCQ with or without azithromycin 
was administered daily over 6 days to 20 people 
infected with SARS ‑CoV‑2 (with various clini‑
cal presentations: from asymptomatic cases to 
overt pneumonia). At the same time, nasopha‑
ryngeal swabs were tested daily to assess viral 
load in the treated patients (as compared with 
the control group not receiving HCQ or azithro‑
mycin). The treatment increased the number of 
SARS ‑CoV‑2‑negative tests in the study group 
compared with the control group from day 3.67 
However, no data on the safety of this treat‑
ment were reported. Although this was an in‑
teresting study, it was limited by methodology 
and a small sample size.
Chloroquine tolerance and cardiovascular toxicity 
Chloroquine is an old antimalarial drug that 
has been widely used for decades in the therapy 
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Other forms of therapy also seem promis‑
ing, including nonsteroidal anti ‑inflammatory 
drugs and low ‑dose corticosteroids; tumor ne‑
crosis factor inhibitors; Janus kinase inhibitors, 
mycophenolate mofetil, tacrolimus, anti ‑CD20 
monoclonal antibodies, and CTLA4‑Ig fusion 
protein. However, firm evidence on the effica‑
cy of these therapies is lacking.86
Vaccine research is ongoing, including several 
studies at an advanced stage (ClinicalTrials.gov 
identifiers, NCT04299724, NCT04276896, 
NCT04283461, NCT04334980, NCT04341389).
Conclusions The current position statement 
is a summary of information on patients with 
COVID‑19 and concomitant HF or at risk of HF. 
We are aware that this document is not conclu‑
sive owing to a limited number of reports, com‑
ing mainly from Chinese and American centers, 
and also owing to the high dynamics of the pan‑
demic. The management of patients with HF dur‑
ing the coronavirus pandemic should be based on 
maintaining current pharmacotherapy in line 
with applicable guidelines of the European Soci‑
ety of Cardiology and the Polish Cardiac Society. 
Indications for elective interventions (revascu‑
larization, electrotherapy, heart valve procedures, 
and others) should be assessed on an individual 
basis and according to the patient’s clinical status, 
with a possibility of rescheduling to a later date. 
Considering the limited contact with the treating 
physician, telemedicine and self ‑monitoring are 
becoming particularly important (http://www.
slabeserce.pl/). As the epidemiological situation 
is unpredictable and the pandemic may be long‑
lasting, it is necessary to change the organization 
of care for HF patients, particularly those at high 
risk, so that the care is provided in dedicated cen‑
ters with measures introduced to ensure the max‑
imum safety and minimal risk of infection.
SUPPLEMENTARY MATERIAL
The  Polish  version  of  the  paper  and  supplementary  material  are  available 
at www.mp.pl/kardiologiapolska.
ARTICLE INFORMATION
CONFLICT OF INTEREST None declared.
OPEN ACCESS This  is  an Open  Access  article  distributed  under  the  terms 
of  the  Creative  Commons  Attribution -Non  Commercial -No  Derivatives  4.0  In-















(eg, palpitations with or without syncope, unex‑
plained syncope, sudden death in the immediate 
family, and cases of drowning in shallow water) 
as well as a careful assessment of concomitant 
drug use to identify other substances potentially 
affecting the QT interval (eg, other antiarrhyth‑
mics, antibacterials, or antipsychotics). Of note, 
the concomitant use of CQ or HCQ with amiod‑
arone increases the risk of severe ventricular ar‑
rhythmias. Therefore, the combined use of these 
drugs is contraindicated.72
In addition, azithromycin, which is used for 
respiratory infections due to SARS ‑CoV‑2, may 
also induce prolonged cardiac repolarization and 
QT interval with the risk of serious ventricular 
arrhythmias.73
It is important to carefully monitor the CQ 
therapy in patients with COVID‑19, including 
pharmacovigilance and a comprehensive assess‑
ment of the safety profile.
Novel perspectives in the treatment of coronavirus 
disease 2019 The concept of cytokine storm has 
led to research on the use of recombinant anti‑
‑IL‑6 or anti ‑IL‑6 receptor antibodies to inhib‑
it the excessive activation of IL‑6. The investi‑
gated drugs include tocilizumab, which targets 
the IL‑6 receptor and possibly modulates the in‑
flammatory process associated with SARS ‑CoV‑2 
infection, as well as several neutralizing mono‑
clonal antibodies targeting the molecular mech‑
anism of SARS ‑CoV and MERS ‑CoV.74,75
TMPRSS2 inhibitors block the  entry of 
SARS ‑CoV‑2 into the cell.76,7 7 A known TMPRSS2 
inhibitor on the market is camostat mesylate.
There are also ongoing trials of antiviral‑
‑specific treatment. Drugs that inhibit viral RNA 
synthesis include remdesivir, favipiravir, and 
ribavirin. Remdesivir is a new nucleotide ana‑
logue with a broad spectrum of antiviral activi‑
ty against single ‑stranded RNA viruses, includ‑
ing the Ebola virus.78-81 The drug inhibits RNA‑
‑dependent RNA polymerase, which is crucial in 
the replication of viral RNA in the host cell. Ani‑
mal model and cell line studies suggested the ef‑
ficacy of remdesivir in the selective inhibition of 
MERS ‑CoV and SARS ‑CoV‑2 infection.78,82 Exper‑
imental treatment with intravenous remdesivir 
in the first patient with COVID‑19 in the United 
States has shown a very promising response.83 
A multicenter randomized placebo ‑controlled 
phase 3 clinical trial to determine the efficacy 
and safety of remdesivir in COVID‑19 is current‑
ly underway.84 A preliminary analysis of data 
from a randomized controlled trial involving 
1063 patients, which was started on February 
21, 2020, showed that hospitalized patients with 
advanced COVID‑19 and lung involvement who 
received remdesivir recovered faster than simi‑
lar patients receiving placebo.85 This is the first 
such clinical trial in the United States to assess 
experimental COVID‑19 treatment.
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